Leerink Partners analyst Marc Goodman has maintained their bullish stance on ACAD stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marc Goodman has given his Buy rating due to a combination of factors that highlight ACADIA Pharmaceuticals’ strong performance and growth potential. The company reported a robust quarter with significant growth in both Nuplazid and Daybue sales, which increased by 7% and 14%, respectively. The expansion of the sales force has successfully driven a record high in unique patients on Daybue therapy, with discontinuation rates remaining below 10%, indicating sustained growth prospects for the franchise.
Additionally, the More to Parkinson’s campaign has effectively increased the adoption of Nuplazid for Parkinson’s disease psychosis, prompting the company to extend the campaign. Despite the stock’s strong performance leading up to the report, Goodman believes that the current pipeline is undervalued, presenting a favorable risk/reward scenario, particularly with upcoming data expected in early 4Q25. The higher-than-expected sales figures for both Nuplazid and Daybue further support the Buy rating, as they indicate strong market demand and effective execution of the company’s strategies.
According to TipRanks, Goodman is a 4-star analyst with an average return of 5.0% and a 47.26% success rate. Goodman covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Evolus, and Axsome Therapeutics.
In another report released yesterday, Citizens JMP also maintained a Buy rating on the stock with a $38.00 price target.